Parental age at birth and risk of adult-onset cancer in female offspring
父母的出生年龄和女性后代成年发病癌症的风险
基本信息
- 批准号:8464031
- 负责人:
- 金额:$ 7.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-01 至 2014-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAchondroplasiaAddressAdolescentAdultAffectAgeApert syndromeApoptosisAutistic DisorderBiologicalBiological MarkersBirthBirth OrderBreastCaliforniaCancer EtiologyCell divisionChildChildhoodChildhood LeukemiaChromosome abnormalityCohort StudiesColonCountryCouplesCox Proportional Hazards ModelsDNA DamageDNA RepairDaughterDevelopmentDiseaseEndometrialEndometrial CarcinomaEnrollmentEpigenetic ProcessEstrogensEtiologyFamily history ofFathersFemaleFertilizationGeneticGenomic ImprintingGerm CellsGestational AgeGoalsGrowthHealthHematologic NeoplasmsHormonesHumanHyperactive behaviorInsulin-Dependent Diabetes MellitusKidneyKnowledgeLeadLengthLinkLungMalignant NeoplasmsMalignant neoplasm of ovaryMalignant neoplasm of pancreasMalignant neoplasm of prostateMalignant neoplasm of thyroidMaternal AgeMothersMutagensMutationNervous System NeoplasmsNon-Hodgkin&aposs LymphomaOnset of illnessOocytesOutcomeOvarianPancreasParental AgesParticipantPaternal AgePerinatal mortality demographicsPredispositionPregnancyPreventionPropertyProspective StudiesPubertyPublishingRegulationRelative RisksRenal carcinomaResearchResourcesRiskRisk FactorsRoleSchizophreniaSchoolsSocioeconomic StatusSoilSpecimenSpermatogoniaTelomeraseTestingThyroid GlandTimeWomanWomen&aposs HealthWorkadvanced maternal ageagedbasecancer diagnosiscancer initiationcancer riskcancer typecarcinogenesischild bearingcohortexperiencefollow-uphigh riskhormone related cancerinsightmalemalignant breast neoplasmmelanomamembermenoffspringprospectiverectalresponseteachertelomeretransmission process
项目摘要
DESCRIPTION (provided by applicant): Childbearing has experienced delays in Western countries in the last several decades. The proportion of births to women aged 30 years and above has risen to its highest level. Similarly, men also tend to defer childbearing to older ages.
We believe that there will be measureable effects of parental age at birth on the health of offspring. The immediate effects of advanced maternal age (e.g., chromosomal abnormalities) and paternal age (e.g., Apert syndrome and achondroplasia) on the health of offspring have been extensively studied. In addition, recent studies have shown that increased paternal age at birth is associated with childhood and adolescent disorders such as schizophrenia, childhood leukemias and nervous system tumors. However, the effects of parental age at birth on the risk of adult-onset cancer have not been extensively investigated. To date, the association with parental age has only been studied for breast cancer, prostate cancer and hematological malignancies. Breast cancer risk is associated with both advanced maternal age and paternal age, but the risk of prostate cancer and hematological malignancies are only associated with advanced paternal age. Biological evidence of higher levels of circulating estrogens with advancing gestational age and higher chance of germ cell mutations and DNA damage from older fathers (but not older mothers) supports the possibility that advanced maternal age may increase the risk of hormone-related cancers; advanced paternal age may be a common risk factor for most types of cancer. Therefore, we aim to evaluate the independent effect of paternal age/maternal age on the risk of the 10 most common adult-onset cancers (not including non- Hodgkin lymphoma on which we have published) among U.S. women, accounting for the effects of birth order, socioeconomic status, and other potential cancer-specific risk factors in the California Teachers Study (CTS). The CTS, a prospective cohort study of 133,479 female California public school professionals, provides a unique opportunity for this aim because it contains both parental age information and an extensive list of potential cancer risk factors related to women's health and particularly to cancer risk. From 1995 through 2009, the incident cases for the specific cancers to be studied are 5007 (breast), 1017 (lung), 843 (colon), 279 (rectal), 1031 (endometrial), 298 (thyroid), 195 (kidney), 486 (ovarian), 337 (pancreatic) and 761 (melanoma). We will use multivariate Cox proportional hazards model to estimate the relative risks associated with maternal age and paternal age, considering cancer-specific risk factors for each cancer outcome. Successful completion of this project will address a gap in knowledge regarding the effect of parental age on adult-onset cancer risk. It will provide insight to further
pursue the biological mechanisms between parental age and cancer risk. The long-term goal of the research is to explore biomarkers that link parental age and cancer risk to clarify etiology, and thus provide potential targets for prevention.
描述(由申请人提供):在过去的几十年里,西方国家的生育经历了延迟。30岁及以上妇女的生育比例已升至最高水平。同样,男性也倾向于将生育推迟到年龄较大的年龄。
我们相信,父母出生时的年龄会对后代的健康产生可衡量的影响。母亲高龄(如染色体异常)和父亲年龄(如Apert综合征和软骨发育不全)对后代健康的直接影响已被广泛研究。此外,最近的研究表明,出生时父亲年龄的增加与儿童和青少年疾病有关,如精神分裂症、儿童白血病和神经系统肿瘤。然而,父母出生时的年龄对成人癌症风险的影响还没有得到广泛的调查。到目前为止,只对乳腺癌、前列腺癌和血液系统恶性肿瘤与父母年龄的关系进行了研究。乳腺癌的风险与母亲的高龄和父亲的年龄有关,但前列腺癌和血液系统恶性肿瘤的风险只与父亲的高龄有关。生物学证据表明,随着胎龄的增加,循环中雌激素水平的提高,以及来自年长父亲(但不是年长母亲)的生殖细胞突变和DNA损伤的可能性更高,这支持了这样一种可能性,即高龄母亲可能会增加与激素相关的癌症的风险;高龄父亲可能是大多数类型癌症的常见风险因素。因此,我们的目标是评估父亲年龄/母亲年龄对美国女性中10种最常见的成人发病癌症(不包括我们已发表的非霍奇金淋巴瘤)风险的独立影响,考虑到出生顺序、社会经济地位和加州教师研究(CTS)中其他潜在的癌症特定风险因素的影响。CTS是一项对133,479名加州公立学校女性专业人员进行的前瞻性队列研究,它为这一目标提供了一个独特的机会,因为它包含了父母年龄信息和与女性健康有关的潜在癌症风险因素的广泛清单,特别是与癌症风险有关的因素。从1995年到2009年,要研究的特定癌症的发病病例分别是5007例(乳腺癌)、1017例(肺癌)、843例(结肠癌)、279例(直肠癌)、1031例(子宫内膜)、298例(甲状腺)、195例(肾脏)、486例(卵巢)、337例(胰腺)和761例(黑色素瘤)。我们将使用多变量COX比例风险模型来估计与母亲年龄和父亲年龄相关的相对风险,并考虑每种癌症结局的特定癌症危险因素。该项目的成功完成将解决关于父母年龄对成人发病癌症风险的影响的知识缺口。它将为进一步
探索父母年龄和癌症风险之间的生物学机制。这项研究的长期目标是探索将父母年龄和癌症风险联系起来的生物标记物,以阐明病因,从而提供潜在的预防目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yani Lu其他文献
Yani Lu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yani Lu', 18)}}的其他基金
Parental age at birth and risk of adult-onset cancer in female offspring
父母的出生年龄和女性后代成年发病癌症的风险
- 批准号:
8302896 - 财政年份:2012
- 资助金额:
$ 7.9万 - 项目类别:
相似海外基金
Exploring the genetic background of normal facial variation to dissect disease expressivity, using achondroplasia as a model.
以软骨发育不全为模型,探索正常面部变异的遗传背景,以剖析疾病的表现力。
- 批准号:
486257 - 财政年份:2022
- 资助金额:
$ 7.9万 - 项目类别:
Studentship Programs
Development of therapeutic drugs fro achondroplasia-Examination of FGFR3 inhibitory effects of meclizine hydrochloride
软骨发育不全治疗药物的研制——盐酸美其嗪对FGFR3抑制作用的考察
- 批准号:
21H03063 - 财政年份:2021
- 资助金额:
$ 7.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidation of the relationship between obesity and type 2 diabetes in achondroplasia
阐明肥胖与软骨发育不全中 2 型糖尿病之间的关系
- 批准号:
19K23996 - 财政年份:2019
- 资助金额:
$ 7.9万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Examination of obesity and insulin resistance for patient cohort and disease-specific iPS cells with achondroplasia
检查患有软骨发育不全的患者群体和疾病特异性 iPS 细胞的肥胖和胰岛素抵抗
- 批准号:
18K07877 - 财政年份:2018
- 资助金额:
$ 7.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Early intervention for children with achondroplasia: self-management and self-efficacy
软骨发育不全儿童的早期干预:自我管理和自我效能
- 批准号:
26861923 - 财政年份:2014
- 资助金额:
$ 7.9万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
8675729 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
8129527 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
8277448 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
8476987 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
7987228 - 财政年份:2010
- 资助金额:
$ 7.9万 - 项目类别:














{{item.name}}会员




